A carregar...

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development

Prostate cancer is globally the second most commonly diagnosed cancer type in men. Recent studies suggest that mutations in DNA repair genes are associated with aggressive forms of prostate cancer and castration resistance. Prostate cancer with DNA repair defects may be vulnerable to therapeutic tar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Genes (Basel)
Main Authors: Virtanen, Verneri, Paunu, Kreetta, Ahlskog, Johanna K., Varnai, Reka, Sipeky, Csilla, Sundvall, Maria
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6723995/
https://ncbi.nlm.nih.gov/pubmed/31357527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/genes10080565
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!